Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence GLEEELQFSLGSKINVK
Primary information
sequence IDSeq_2832
Peptide sequenceGLEEELQFSLGSKINVK
CancerPDF_ID CancerPDF_ID902, CancerPDF_ID9479, CancerPDF_ID9625,
PMID19795908,26379225,21533267
Protein NameComplement C4-B,Complement C4-A/Complement C4-B,Complement C4-B
UniprotKB Entry NameCO4B_HUMAN,"CO4A_HUMAN,CO4B_HUMAN",CO4B_HUMAN
FluidPlasma,Plasma,Serum
M/Z946.01,1891.02,630.99
Charge2,NA,3
Mass (in Da)NA,NA,NA
fdrNA,NA,NA
Profiling TechniqueLC-MS,MALDI-TOF,LC-MS
Peptide Identification techniqueMALDI-TOF/TOF,MALDI-TOF/TOF,LC/MS/MS
Quantification TechniqueLC-MRM (multiple reaction monitoring),NA,Multiple Reaction Monitoring
Labelled/Label FreeLabelled,Label Free,Label Free
FDRless than 7%,NA,1.49
CancerPDF_ID CancerPDF_ID902, CancerPDF_ID9479, CancerPDF_ID9625,
p-ValueNA,NA,NA
SoftwareFlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.3),MASCOT
Length17,17,17
Cancer TypeDuctal adenocarcinoma of the pancreas (DAP),Colorectal cancer,Lung adenocarcinoma
DatabaseNCBI refseq Protein Database,UniprotKB,Swissprot Database (57.4)
ModificationNA,NA,NA
Number of Patients"42 normal, 28 patients","94 patients with CRC, 23 with liver metastasis from CRC (histologically defined) and 34 subjects, which underwent colonoscopy and resulted negative",62 lung adenocarcinoma and 30 healthy control
RegulationNA,"Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups.","Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal"
ValidationNA,NA,MRM-based validation of 19 candidates
SensitivityNA,NA,NA
SpecificityNA,NA,NA
AccuracyNA,NA,NA
Peptide AtlasPeptideAtlas
IEDB462023